Clinical Trials Browser

Phase 2/3 × lenvatinib × Thoracic × Clear all

NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Phase 2/3 Terminated

Advanced Non-small Cell Lung Cancer